Philadelphia's CHOP marked its 500th fetal spina bifida repair as a Baltimore mother credits the team for son Owen's care.

Dr. David Hartman met his wife at Temple University while training to become Philadelphia's first blind medical graduate in 1976.

A six-month-old Alaska baby became the youngest CHOP patient to receive gene therapy for metachromatic leukodystrophy. His case underscores the race to diagnose MLD before symptoms begin.

A Wistar-led study traces ovarian cancer’s chemotherapy resistance to an inflammatory chain involving IL-1β, neutrophils and tumor-protecting traps.

AHRQ withheld continuation awards for dozens of projects, forcing Penn and CHOP to pause studies and shutter training programs amid mounting legal and policy fights.

Wistar Institute researchers used a DNA 'knob-into-hole' platform to make multivalent bispecific T‑cell engagers that slowed ovarian tumor growth in preclinical tests.

After a roughly $178M share of the Moderna settlement, Warminster’s Arbutus filed three international patent suits against Pfizer and BioNTech and signaled plans to return capital to shareholders.

Thomas Jefferson University will open a Sidney Kimmel Medical College campus in Allentown, adding more than 54,000 square feet of teaching and lab space and expanding clinical ties with LVHN.

Philly nurses created Vasowatch, a heart‑rate algorithm that flags uterine fatigue hours before postpartum hemorrhage. New NIH funding will support a planned multisite trial.

An investigational implant at Jefferson Moss‑Magee Rehab helped a paralyzed Philadelphia man regain a functional grip, letting him feed himself and write again.

Pennsylvania awarded LCCC $5 million to stand up hands‑on training to prepare local workers for jobs at Eli Lilly’s $3.5B Lehigh Valley plant. The program will mirror Wake Tech’s apprenticeship model.

Remix Therapeutics has agreed to a reverse merger with Passage Bio and lined up an oversubscribed $100M private placement to fund REM‑422 into pivotal readouts.

A 55‑ton cyclotron rolled into University City this week, marking a milestone for Penn Medicine’s $224M Roberts Proton Therapy Center set to open in late 2027.